Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 8, 2020
December 8, 2020
5574de95-cac8-42dc-9e8f-20bb345394e6
Related Documents
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry
Guidance DocumentJanuary 9, 2026Center for Drug Evaluation and Research
Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff
Guidance DocumentDecember 12, 2018Center for Drug Evaluation and Research
Development of a Shared System REMS Guidance for Industry
Guidance DocumentJune 1, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox